BioGeometry and Hanhe Bio Forge Strategic Partnership to Build Generative AI-Powered High-Efficiency Cell Factories

Source: BioGeometry

May 29,BioGeometry and Nanning Handoo Biotechnology Co., Ltd. Hold Strategic Cooperation Signing Ceremony on "AI-Driven Synthetic Biology Technology to Accelerate the Construction of Cell Factories"The two parties will deeply collaborate on core technologies such as generative AI-driven enzyme design, enzyme mining, strain modification, metabolic pathway optimization, and cell factory design, promoting the deep integration and application of "artificial intelligence + synthetic biology."

By leveraging machine learning to precisely analyze massive genomic and metabolomic data, BioGeometry's first full-scenario atomic-level protein large model, GeoFlow V2, can achieve optimal gene editing site prediction and metabolic pathway reconstruction. This reduces the traditional "trial-and-error" strain development cycle from months or even years to just weeks, significantly enhancing the R&D efficiency of cell factories and product performance.

As one of the largest private synthetic biology production enterprises in Guangxi Province, Hanhe Bio has been focusing on green manufacturing, biostimulants, microbial fertilizers, and novel functional raw materials in recent years. Its products are widely used in multiple industries such as agriculture, food, and medical aesthetics. The company operates research and development centers in Nanning and Shenzhen with a total area exceeding 12,000 square meters, equipped with a high-level scientific research team and advanced experimental facilities. It is a representative of national high-tech enterprises and a "specialized, refined, distinctive, and innovative" enterprise in Guangxi.

Yu Yifa, Vice General Manager of Hannbio, stated: "Hannbio always regards R&D innovation as the core driving force of the enterprise. This collaboration with BioGeometry means that we will make significant strides in the AI-empowered synthetic biology track, achieving a systematic leap from fundamental design logic to industrial application."

Dr. Jian Tang, founder and CEO of BioGeometry, stated: "As a significant breakthrough in generative AI within the biomanufacturing field, GeoFlow V2 is driving protein design towards an intelligent and scalable future. We are excited to partner with Hando Biotech to integrate AI capabilities into the core processes of traditional fermentation industries, co-creating more efficient and sustainable smart cell factory solutions."

As practitioners of the national strategies of "Artificial Intelligence+" and "Biological Manufacturing," both parties will use Hando Bio's existing microbial strain development needs as a starting point to build a closed-loop R&D process covering "target prediction—protein generation—functional verification—metabolic pathway optimization." At the same time, they will continue to explore directions such as metabolic engineering and green substitution of raw materials, injecting innovative momentum into global sustainable development and jointly promoting the value leap of China's biological manufacturing in the global industrial chain.

About BioGeometry

BioGeometry

BioGeometry is a generative AI-driven protein design and R&D platform company, dedicated to providing bio-manufacturing solutions for traditional manufacturing enterprises to achieve green and intelligent transformation. The company leverages large generative artificial intelligence (AIGC) models to understand the language of life, building multimodal large models that bridge natural language and protein language. It redefines the process of protein drug discovery and design, focusing on creating programmable proteins for applications in biomedicine and bio-manufacturing.

Founded in 2022 by Dr. Jian Tang, a top scientist in AI-driven drug discovery, with Yoshua Bengio, the father of deep learning and Turing Award winner, serving as the Chief Scientific Advisor. The company has developed two core platforms: an AI-powered large molecule drug design platform and a high-throughput wet lab validation system for large molecule drugs, achieving a closed-loop integration of dry and wet experiments. It is currently empowering partners to enable precise and efficient large molecule drug design and optimization.